DarioHealth DRIO shares are trading higher after Aegis Capital maintained its Buy rating on the stock and raised its price target from $25 to $35 per share.
DarioHealth Corp is a digital health company. It is engaged in the development and commercialization of patented and proprietary technology that provides consumers with laboratory-testing capabilities using smartphones and other mobile devices.
The company's product, Dario Blood sugar monitor is a mobile, real-time, cloud-based, diabetes management solution based on a multi-featured software application combined with a blood glucose monitoring device.
DarioHealth shares were trading up 8.88% at $27.21. The stock has a 52-week high of $27.59 and low of $3.02.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
